Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036

Core Insights - Axsome Therapeutics is gaining prominence in the biotech sector, outperforming broader equities over the past five years and showing potential for continued strong performance over the next decade [1][2] Company Overview - Axsome Therapeutics specializes in developing medicines for central nervous system conditions, with approved products like Auvelity for depression and Symbravo for migraines [4] - The company is also advancing AXS-12 for narcolepsy, which has completed phase 3 clinical trials, with regulatory submissions expected in Q4 [6] Market Opportunity - The market for Alzheimer's disease (AD) agitation, which affects over 5 million patients in the U.S., presents a significant commercial opportunity, especially as the aging population increases [5] - Auvelity is positioned to enter a growing market with high unmet needs and limited competition [5] Financial Potential - Axsome's late-stage pipeline has a peak sales potential exceeding $16 billion, while the current market cap stands at $9.3 billion [8] - The company enjoys a gross margin of 90.31% and has patent protection for its products until the 2040s, mitigating risks associated with patent cliffs [8]